HRP20221319T1 - Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka - Google Patents
Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka Download PDFInfo
- Publication number
- HRP20221319T1 HRP20221319T1 HRP20221319TT HRP20221319T HRP20221319T1 HR P20221319 T1 HRP20221319 T1 HR P20221319T1 HR P20221319T T HRP20221319T T HR P20221319TT HR P20221319 T HRP20221319 T HR P20221319T HR P20221319 T1 HRP20221319 T1 HR P20221319T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- use according
- pancreatic cancer
- combination
- cancer
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims 4
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 102000002029 Claudin Human genes 0.000 title 1
- 108050009302 Claudin Proteins 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 12
- 201000002528 pancreatic cancer Diseases 0.000 claims 12
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 12
- 229960005277 gemcitabine Drugs 0.000 claims 8
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 208000037819 metastatic cancer Diseases 0.000 claims 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 3
- 229960001756 oxaliplatin Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 229940122361 Bisphosphonate Drugs 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 239000002269 analeptic agent Substances 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 230000009089 cytolysis Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims 1
- 208000006336 acinar cell carcinoma Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 229960004343 alendronic acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960002286 clodronic acid Drugs 0.000 claims 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 230000036732 histological change Effects 0.000 claims 1
- 229960005236 ibandronic acid Drugs 0.000 claims 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical class OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 claims 1
- 229950011129 minodronic acid Drugs 0.000 claims 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 claims 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- -1 nitrogen-containing bisphosphonate Chemical class 0.000 claims 1
- 229950004969 olpadronic acid Drugs 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229960003978 pamidronic acid Drugs 0.000 claims 1
- 210000000277 pancreatic duct Anatomy 0.000 claims 1
- 229960000759 risedronic acid Drugs 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Claims (21)
1. Antitijelo za uporabu u postupku za liječenje ili prevenciju raka gušterače, naznačeno time, što stanice raka gušterače eksprimiraju CLDN18.2, pri čemu navedeni postupak sadrži davanje pacijentu (i) antitijela i (ii) sredstva koji stabilizira ili povećava ekspresiju CLDN18.2, gdje
(a) antitijelo se veže za CLDN18.2 i posreduje u ubijanju stanica koje eksprimiraju CLDN18.2, pri čemu antitijelo sadrži teški lanac antitijela koji sadrži aminokiselinsku sekvencu predstavljenu sekvencom SEQ ID NO: 32 i laki lanac antitijela koji sadrži aminokiselinsku sekvencu predstavljenu sekvencom SEQ ID NO: 39, i
(b) sredstvo je kemoterapijsko sredstvo izabrano iz grupe koja se sastoji od gemcitabina i njegovog prolijeka ili soli, pri čemu je prolijek ester,
gdje, izborno, postupak dodatno sadrži primjenu najmanje jednog dodatnog kemoterapijskog sredstva.
2. Antitijelo za uporabu prema patentnom zahtjevu 1, pri čemu postupak sadrži primjenu kombinacije gemcitabina i oksaliplatina, kombinacije gemcitabina i cisplatina, kombinacije gemcitabina i karboplatina ili kombinacije oksaliplatina, 5-fluorouracila i irinotekana.
3. Antitijelo za uporabu prema patentnom zahtjevu 1 ili 2, pri čemu postupak sadrži primjenu folinske kiseline, oksaliplatina, 5-fluorouracila i irinotekana.
4. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 3, gdje teški lanac antitijela sadrži aminokiselinsku sekvencu predstavljenu sekvencom SEQ ID NO: 17 i laki lanac antitijela sadrži aminokiselinsku sekvencu predstavljenu sekvencom SEQ ID NO: 24.
5. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, gdje postupak dodatno sadrži primjenu sredstvo koje stimulira γδ T stanice, pri čemu su γδ T stanice poželjno Yγ9Vδ2 T stanice, i navedeno sredstvo koje stimulira γδ T stanice je poželjno bisfosfonat, i poželjnije bisfosfonat koji sadrži dušik (aminobisfosfonat).
6. Antitijelo za uporabu prema patentnom zahtjevu 5, gdje je sredstvo koje stimulira γδ T stanice odabrano iz grupe koja se sastoji od zoledronske kiseline, klodronske kiseline, ibandronske kiseline, pamidronske kiseline, risedronske kiseline, minodronske kiseline, olpadronske kiseline, alendronske kiseline, inkadronske kiseline i njihovih soli.
7. Antitijelo za uporabu prema patentnom zahtjevu 5 ili 6, gdje se sredstvo koje stimulira γδ T stanice primjenjuje u kombinaciji sa interleukinom-2.
8. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 7, gdje antitijelo posreduje u ubijanju stanica putem jednog ili više mehanizama od lize posredovane citotoksinošću zavisnom od komplementa (CDC) i lize posredovane staničnom citotoksinošću ovisnom o antitijelima (ADCC).
9. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 8, gdje je antitijelo izabrano iz grupe koja se sastoji od (i) antitijela koje je proizvedeno pomoću, i/ili se može dobiti iz, klona deponiranog pod pristupnim br. DSM ACC2810, (ii) antitijela koje predstavlja himerizirani ili humanizirani oblik antitijela pod (i), i (iii) antitijela koje sadrži antigen-vezujući dio ili antigen-vezujuće mjesto, konkretno varijabilnu regiju, antitijela pod (i).
10. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu postupak sadrži primjenu antitijela u dozi do 1000 mg/m2 ili ponovljeno, u dozi od 300 do 600 mg/m2.
11. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, gdje rak gušterače sadrži primarni rak, uznapredovali rak ili metastatski rak, ili njihovu kombinaciju, kao što je kombinacija primarnog raka gušterače i metastatskog raka.
12. Antitijelo za uporabu prema patentnom zahtjevu 11, gdje metastatski rak sadrži metastazu na limfne čvorove, jajnik, jetru ili pluća, ili njihovu kombinaciju.
13. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 12, gdje rak gušterače sadrži rak gušterače kanala.
14. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 13, gdje rak gušterače sadrži adenokarcinom ili karcinom, ili njihovu kombinaciju.
15. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 14, gdje rak gušterače sadrži duktalni adenokarcinom, mucinozni adenokarcinom, neuroendokrini karcinom ili karcinom acinarnih stanica, ili njihovu kombinaciju.
16. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 15, gdje je rak gušterače djelomično ili potpuno refraktoran na liječenje gemcitabinom, kao što je monoterapija gemcitabinom.
17. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 16, gdje prevencija raka gušterače sadrži prevenciju pojave recidiva raka gušterače.
18. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 17, gdje je pacijent imao kiruršku intervenciju zbog raka gušterače.
19. Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1 do 18, gdje pacijent ima prekanceroznu leziju gušterače, konkretno, prekanceroznu leziju gušterače koja sadrži početnu malignu histološku promjenu u kanalima gušterače.
20. Medicinski preparat za uporabu u liječenju ili prevenciji raka gušterače, gdje navedeni medicinski preparat sadrži (i) antitijelo koje se veže za CLDN18.2 i posreduje u ubijanju stanica koje eksprimiraju CLDN18.2, pri čemu antitijelo sadrži teški lanac antitijela koji sadrži aminokiselinsku sekvencu predstavljenu sekvencom SEQ ID NO: 32 i laki lanac antitijela koji sadrži aminokiselinsku sekvencu predstavljenu sekvencom SEQ ID NO: 39 i (ii) gemcitabin.
21. Medicinski preparat za uporabu prema patentnom zahtjevu 20, koji je prisutan u obliku kompleta, koji sadrži prvu posudu koja uključuje antitijelo i drugu posudu koja uključuje gemcitabin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/000505 WO2014127785A1 (en) | 2013-02-20 | 2013-02-20 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| PCT/EP2014/000433 WO2014127906A1 (en) | 2013-02-20 | 2014-02-18 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP14707647.5A EP2958945B1 (en) | 2013-02-20 | 2014-02-18 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221319T1 true HRP20221319T1 (hr) | 2022-12-23 |
Family
ID=54602082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221319TT HRP20221319T1 (hr) | 2013-02-20 | 2014-02-18 | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka |
Country Status (4)
| Country | Link |
|---|---|
| EP (2) | EP2958945B1 (hr) |
| CY (1) | CY1126041T1 (hr) |
| HR (1) | HRP20221319T1 (hr) |
| RS (1) | RS63738B1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109337870B (zh) * | 2018-12-24 | 2020-07-03 | 广东暨德康民生物科技有限责任公司 | 人Vγ9Vδ2T细胞扩增方法与培养基 |
| WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
| CN116536274B (zh) * | 2023-06-20 | 2023-09-19 | 上海精翰生物科技有限公司 | Claudin18.2表达稳转细胞株、制备方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス，インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| SI1558648T1 (sl) | 2002-10-17 | 2012-05-31 | Genmab As | Človeška monoklonalna protitelesa proti CD |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
-
2014
- 2014-02-18 EP EP14707647.5A patent/EP2958945B1/en active Active
- 2014-02-18 HR HRP20221319TT patent/HRP20221319T1/hr unknown
- 2014-02-18 RS RS20221045A patent/RS63738B1/sr unknown
- 2014-02-18 EP EP22201152.0A patent/EP4177273A1/en active Pending
-
2022
- 2022-11-23 CY CY20221100748T patent/CY1126041T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4177273A1 (en) | 2023-05-10 |
| CY1126041T1 (el) | 2023-11-15 |
| RS63738B1 (sr) | 2022-12-30 |
| EP2958945B1 (en) | 2022-10-19 |
| EP2958945A1 (en) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015139901A (ru) | Комбинированная терапия с использованием антител против клаудина 18.2 для лечения рака | |
| JP2018002724A5 (hr) | ||
| HRP20201859T1 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| RU2014152107A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| HRP20210440T1 (hr) | Kombinirana terapija za rak | |
| RU2017117664A (ru) | Комбинация | |
| HRP20201656T1 (hr) | Neutralizacija inhibitornih putova u limfocitima | |
| JP2018070648A5 (hr) | ||
| WO2017079746A3 (en) | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer | |
| JP2018508512A5 (hr) | ||
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| JP2016006096A5 (hr) | ||
| JP2018516911A5 (hr) | ||
| HRP20171218T1 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje karcinoma | |
| RU2018140960A (ru) | Композиции, содержащие комбинированный состав на основе антител к pd-l1 и ctla-4 | |
| IL292658A (en) | Immune modulation with tlr9 agonists for cancer therapy | |
| JP2016520082A5 (hr) | ||
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2018525358A5 (hr) | ||
| MY176246A (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| RU2018134336A (ru) | Комбинированная терапия сорафенибом или регорафенибом и фосфорамидатным пролекарством троксацитабина | |
| HRP20221319T1 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| RU2018125603A (ru) | Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| JP2014523421A5 (hr) |